All In Biotech

Free tool

FAERS Monitor: Motofen Half-Strength

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017744 or its brand name (Motofen Half-Strength, Atropine Sulfate, Difenoxin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

26

Serious

15

58% of reports

Hospitalization

10

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting4
  • diarrhoea3
  • drug ineffective3
  • nausea3
  • pain3
  • product dose omission issue3
  • bone disorder2
  • fall2
  • irritable bowel syndrome2
  • product availability issue2
  • abdominal distension1
  • abdominal pain1
  • abdominal pain upper1
  • arthrodesis1
  • asthenia1

Reports by year received

View as table
YearReports
20043
20052
20061
20071
20111
20131
20161
20175
20191
20202
20212
20223
20253

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
arthrodesis1796.2116.4198
bone disorder288.823.597
irritable bowel syndrome275.519.982
product availability issue271.118.877
product dose omission issueSignal38.32.813
abdominal distension17.71.11
vomitingSignal46.92.815
fall24.91.33
painSignal34.01.44
abdominal pain upper13.90.60
diarrhoea33.81.34
abdominal pain13.50.50
nausea33.11.12
asthenia12.20.30
drug ineffective31.80.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.